For more information visit http://www.astrazeneca-us.com.
The statements contain herein include forward-looking statements.
Although we believe our expectations are based on reasonable assumptions,
any forward-looking statements, by their very nature, involve risks and
uncertainties and may be influenced by factors that could cause actual
outcomes and results to be materially different from those predicted. The
forward-looking statements reflect knowledge and information available at
the date of the preparation of this press release and the Company
undertakes no obligation to update these forward-looking statements.
Important factors that could cause actual results to differ materially from
those contained in forward-looking statements, certain of which are beyond
our control, include, among other things, those risk factors identified in
the Company's Annual Report/Form 20-F for 2006. Nothing contained herein
should be construed as a profit forecast.
* The Montgomery-Asberg Depression Rating Scale (MADRS) measures the
severity of a number of depressive symptoms including sadness, tension,
sleep, appetite, energy, concentration, and suicidal ideation. The MADRS
score decreases as depressive symptoms improve.(5)
1. National Alliance on Mental Illness: Major Depression Fact Sheet. 2007. Available at:
gge dPageDisplay.cfm&TPLID=54&ContentID=26414 (Due to length of URL, please
and paste into browser). Accessed November 30, 2007.
2. Nemeroff, CB. Prevalence and Management of Treatment-Resistant
Depression. J Clin Psychiatry. 2007;68:17-25.
3. American Psychiatric Association. Prac
Copyright©2008 PR Newswire.
All rights reserved